Next Article in Journal
Network of Palladium-Based Nanorings Synthesized by Liquid-Phase Reduction Using DMSO-H2O: In Situ Monitoring of Structure Formation and Drying Deformation by ASEM
Next Article in Special Issue
Infusion of Plasma from Exercised Mice Ameliorates Cognitive Dysfunction by Increasing Hippocampal Neuroplasticity and Mitochondrial Functions in 3xTg-AD Mice
Previous Article in Journal
Elimination of Teratogenic Human Induced Pluripotent Stem Cells by Bee Venom via Calcium-Calpain Pathway
Previous Article in Special Issue
Tetragonia tetragonioides Protected against Memory Dysfunction by Elevating Hippocampal Amyloid-β Deposition through Potentiating Insulin Signaling and Altering Gut Microbiome Composition
Article

Peptide Interference with APP and Tau Association: Relevance to Alzheimer’s Disease Amelioration

1
Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel
2
Department of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel
3
Department of Veterinary Resources, Weizmann Institute of Science, Rehovot 76100, Israel
4
Department of Biomolecular Science, Weizmann Institute of Science, Rehovot 76100, Israel
5
Department of Neurobiology, School of Neurobiology, Biochemistry and Biophysics, The George S. Wise Faculty of Life Sciences, Sagol School of Neuroscience Tel Aviv University, Tel Aviv 6997801, Israel
*
Author to whom correspondence should be addressed.
Present address: Department of Chemistry, Utrecht University, Ultrecht 3584 CH, The Netherlands.
Int. J. Mol. Sci. 2020, 21(9), 3270; https://doi.org/10.3390/ijms21093270
Received: 1 March 2020 / Revised: 27 April 2020 / Accepted: 29 April 2020 / Published: 5 May 2020
The two major proteins involved in Alzheimer’s disease (AD) are the amyloid precursor protein (APP) and Tau. Here, we demonstrate that these two proteins can bind to each other. Four possible peptides APP1 (390–412), APP2 (713–730), Tau1 (19–34) and Tau2 (331–348), were predicted to be involved in this interaction, with actual binding confirmed for APP1 and Tau1. In vivo studies were performed in an Alzheimer Disease animal model—APP double transgenic (Tg) 5xFAD—as well as in 5xFAD crossed with Tau transgenic 5xFADXTau (FT), which exhibit declined cognitive reduction at four months of age. Nasal administration of APP1 and Tau1 mixture, three times a week for four or five months, reduced amyloid plaque burden as well as the level of soluble Aβ 1–42 in the brain. The treatment prevented the deterioration of cognitive functions when initiated at the age of three months, before cognitive deficiency was evident, and also at the age of six months, when such deficiencies are already observed, leading to a full regain of cognitive function. View Full-Text
Keywords: APP and Tau protein; synthetic peptides; Alzheimer’s disease; cognitive function; amyloid plaques APP and Tau protein; synthetic peptides; Alzheimer’s disease; cognitive function; amyloid plaques
Show Figures

Figure 1

MDPI and ACS Style

Maron, R.; Armony, G.; Tsoory, M.; Wilchek, M.; Frenkel, D.; Arnon, R. Peptide Interference with APP and Tau Association: Relevance to Alzheimer’s Disease Amelioration. Int. J. Mol. Sci. 2020, 21, 3270. https://doi.org/10.3390/ijms21093270

AMA Style

Maron R, Armony G, Tsoory M, Wilchek M, Frenkel D, Arnon R. Peptide Interference with APP and Tau Association: Relevance to Alzheimer’s Disease Amelioration. International Journal of Molecular Sciences. 2020; 21(9):3270. https://doi.org/10.3390/ijms21093270

Chicago/Turabian Style

Maron, Ruth, Gad Armony, Michael Tsoory, Meir Wilchek, Dan Frenkel, and Ruth Arnon. 2020. "Peptide Interference with APP and Tau Association: Relevance to Alzheimer’s Disease Amelioration" International Journal of Molecular Sciences 21, no. 9: 3270. https://doi.org/10.3390/ijms21093270

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop